- Home
- HYI vs ITOS Comparison
HYI vs ITOS Comparison
Compare HYI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- ITOS
- Stock Information
- Founded
- HYI 2010
- ITOS 2011
- Country
- HYI United States
- ITOS United States
- Employees
- HYI N/A
- ITOS N/A
- Industry
- HYI Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYI Finance
- ITOS Health Care
- Exchange
- HYI Nasdaq
- ITOS Nasdaq
- Market Cap
- HYI 266.3M
- ITOS 280.6M
- IPO Year
- HYI N/A
- ITOS 2020
- Fundamental
- Price
- HYI $12.01
- ITOS $8.06
- Analyst Decision
- HYI
- ITOS Strong Buy
- Analyst Count
- HYI 0
- ITOS 3
- Target Price
- HYI N/A
- ITOS $21.33
- AVG Volume (30 Days)
- HYI 50.6K
- ITOS 470.7K
- Earning Date
- HYI 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- HYI 9.59%
- ITOS N/A
- EPS Growth
- HYI N/A
- ITOS N/A
- EPS
- HYI N/A
- ITOS N/A
- Revenue
- HYI N/A
- ITOS $35,000,000.00
- Revenue This Year
- HYI N/A
- ITOS $271.18
- Revenue Next Year
- HYI N/A
- ITOS N/A
- P/E Ratio
- HYI N/A
- ITOS N/A
- Revenue Growth
- HYI N/A
- ITOS N/A
- 52 Week Low
- HYI $10.99
- ITOS $7.09
- 52 Week High
- HYI $12.24
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- HYI 52.42
- ITOS 54.92
- Support Level
- HYI $11.83
- ITOS $7.63
- Resistance Level
- HYI $12.00
- ITOS $8.09
- Average True Range (ATR)
- HYI 0.09
- ITOS 0.31
- MACD
- HYI 0.02
- ITOS 0.07
- Stochastic Oscillator
- HYI 86.84
- ITOS 78.07
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.